ZYANBII Trademark

Trademark Overview


On Thursday, February 20, 2025, a trademark application was filed for ZYANBII with the United States Patent and Trademark Office. The USPTO has given the ZYANBII trademark a serial number of 99048590. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, February 9, 2026. This trademark is owned by Zenas BioPharma, Inc.. The ZYANBII trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biological preparations for medical purposes, namely, immunology-based therapies for autoimmune diseases; Pharmaceutical and biological preparations for use in inflammation, immunology, rheumatology, neurology, gastroenterology, dermatology, and hematology for medical purposes; Therapeutic agents, namely, monoclonal antibodies for inhibiting the production and proliferation of autoantibodies, cytokine secretion, and other inflammatory proteins, and antigen uptake for medical purposes; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing autoimmune diseases, inflammatory diseases, immunoglobulin G4-related disease (IgG4-RD), multiple sclerosis, lupus, autoimmune hemolytic anemia, rheumatoid arthritis, and diseases, disorders, and conditions of the immune system
zyanbii

General Information


Serial Number99048590
Word MarkZYANBII
Filing DateThursday, February 20, 2025
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateMonday, February 9, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 3, 2026

Trademark Statements


Goods and ServicesPharmaceutical and biological preparations for medical purposes, namely, immunology-based therapies for autoimmune diseases; Pharmaceutical and biological preparations for use in inflammation, immunology, rheumatology, neurology, gastroenterology, dermatology, and hematology for medical purposes; Therapeutic agents, namely, monoclonal antibodies for inhibiting the production and proliferation of autoantibodies, cytokine secretion, and other inflammatory proteins, and antigen uptake for medical purposes; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing autoimmune diseases, inflammatory diseases, immunoglobulin G4-related disease (IgG4-RD), multiple sclerosis, lupus, autoimmune hemolytic anemia, rheumatoid arthritis, and diseases, disorders, and conditions of the immune system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, February 20, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameZenas BioPharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events


Event DateEvent Description
Thursday, February 20, 2025NEW APPLICATION ENTERED
Thursday, February 20, 2025APPLICATION FILING RECEIPT MAILED
Thursday, February 20, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, July 25, 2025ASSIGNED TO EXAMINER
Wednesday, July 30, 2025NON-FINAL ACTION WRITTEN
Wednesday, July 30, 2025NON-FINAL ACTION E-MAILED
Wednesday, July 30, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 23, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, October 23, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, February 3, 2026TEAS PETITION TO REVIVE RECEIVED
Tuesday, February 3, 2026PETITION TO REVIVE-GRANTED
Tuesday, February 3, 2026NOTICE OF REVIVAL - E-MAILED
Tuesday, February 3, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 3, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 3, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 4, 2026APPROVED FOR PUB - PRINCIPAL REGISTER